financetom
Business
financetom
/
Business
/
Travel + Leisure Q2 Adjusted Earnings, Net Revenue Rise; Offers Q3, Full Year Adjusted EBITDA Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Travel + Leisure Q2 Adjusted Earnings, Net Revenue Rise; Offers Q3, Full Year Adjusted EBITDA Guidance
Jul 24, 2024 4:34 AM

07:02 AM EDT, 07/24/2024 (MT Newswires) -- Travel + Leisure ( TNL ) reported Q2 adjusted earnings Wednesday of $1.52 per diluted share, up from $1.33 a year earlier.

Analysts polled by Capital IQ expected $1.41.

Net revenue for the quarter ended on June 30 was $985 million, up from $949 million a year earlier.

Analysts surveyed by Capital IQ expected $987.2 million.

The company expects Q3 adjusted EBITDA of $235 million to $245 million. Analysts polled by Capital IQ expect $238.7 million. The company updated its full-year adjusted EBITDA to a new range of $915 million to $935 million versus the prior outlook of $910 million to $930 million. Analysts polled by Capital IQ expect $921.6 million.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Gold Road Rejects Gold Fields' 'Opportunistic' Bid, Criticizes Timing, Terms
Gold Road Rejects Gold Fields' 'Opportunistic' Bid, Criticizes Timing, Terms
Mar 24, 2025
Gold Fields Ltd ( GFI ) submitted a non-binding, indicative, and conditional offer to acquire 100% of Gold Road Resources Ltd ( ELKMF ) for A$3.05 per share. The March 7 proposal, announced on Monday, included A$2.27 in fixed cash and a variable component linked to Gold Road's stake in De Grey Mining. As of March 21, the offer valued...
Abbott Laboratories Gets FDA Approval to Assess Investigational Device in Heart Disease Clinical Trial
Abbott Laboratories Gets FDA Approval to Assess Investigational Device in Heart Disease Clinical Trial
Mar 24, 2025
10:20 AM EDT, 03/24/2025 (MT Newswires) -- Abbott Laboratories ( ABT ) said Monday that its Coronary Intravascular Lithotripsy System has received an investigational device exemption from the US Food and Drug Administration. The company said its intravascular lithotripsy clinical trial, which aims to improve outcomes in coronary artery disease patients, will enroll up to 335 people in 47 locations...
Kazakhstan continues oil supply via CPC pipeline in normal mode, IFX reports
Kazakhstan continues oil supply via CPC pipeline in normal mode, IFX reports
Mar 24, 2025
MOSCOW, March 24 (Reuters) - Kazakhstan is continuing to supply oil via the CPC pipeline in normal mode, Interfax news agency reported on Monday. Earlier the Russian Defence Ministry said that Ukraine had attempted a drone attack on the Kropotkinskaya pumping station on the CPC pipeline in Russia's Krasnodar region on Monday. ...
Vertiv Holdings Unusual Options Activity
Vertiv Holdings Unusual Options Activity
Mar 24, 2025
Investors with a lot of money to spend have taken a bullish stance on Vertiv Holdings ( VRT ) . And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this...
Copyright 2023-2026 - www.financetom.com All Rights Reserved